Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: EMPA-KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan. METHODS: Eligibility required an estimated glomerular filtration rate (eGFR) of ≥ 20 

Original publication

DOI

10.1007/s10157-024-02489-4

Type

Journal

Clin Exp Nephrol

Publication Date

06/2024

Volume

28

Pages

588 - 595

Keywords

Cardiovascular disease, Kidney function, Randomised trial, Sodium–glucose co-transporter-2 inhibitor, Humans, Glucosides, Renal Insufficiency, Chronic, Male, Benzhydryl Compounds, Female, Middle Aged, Glomerular Filtration Rate, Japan, Aged, Sodium-Glucose Transporter 2 Inhibitors, Disease Progression, Albuminuria, Treatment Outcome, Kidney, Double-Blind Method, Kidney Failure, Chronic, Cardiovascular Diseases